Arhalofenate
Structural formula | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||||||||
Non-proprietary name | Arhalofenate | |||||||||||||||
other names |
|
|||||||||||||||
Molecular formula | C 19 H 17 ClF 3 NO 4 | |||||||||||||||
External identifiers / databases | ||||||||||||||||
|
||||||||||||||||
Drug information | ||||||||||||||||
ATC code | ||||||||||||||||
Drug class | ||||||||||||||||
Mechanism of action | ||||||||||||||||
properties | ||||||||||||||||
Molar mass | 415,80 g · mol -1 | |||||||||||||||
safety instructions | ||||||||||||||||
|
||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Arhalofenate is a potential drug in clinical development to be used as an anti-diabetic drug in the treatment of type 2 diabetes . Chemically it is the ( R ) - enantiomer of the halofenate . Arhalofenate is a prodrug and as such is only converted into its active form, the free ( R ) - (4-chlorophenyl) - (3-trifluoromethylphenoxy) acetic acid, in the organism .
This mediates its effects as a partial agonist via peroxisome proliferator-activated receptors γ (PPARγ). In animal experiments , arhalofenate has been shown to have an insulin sensitizing and blood sugar lowering effect. In addition, arhalofenate lowers the level of triglycerides in the blood through a mechanism that is as yet unknown.
Arhalofenate is being developed by the US pharmaceutical company Metabolex .
Stereochemistry
Arhalofenate is the active ( R ) - enantiomer , the eutomer , of the racemic drug halofenate [1: 1 mixture of ( R ) - and ( S ) -enantiomer] with a stereocenter.
Individual evidence
- ↑ harmonized classification for this substance . A label of [No public or meaningful name is available] in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed on November 6, 2019, is derived from a self-classification by the distributor . There is not yet a
- ↑ Data sheet MBX-102 from Sigma-Aldrich , accessed on February 16, 2020 ( PDF ).
- ↑ Entry on arhalofenate. In: Römpp Online . Georg Thieme Verlag, accessed on December 3, 2019.
- ^ Gregoire FM, Zhang F, Clarke HJ, et al. : MBX-102 / JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema . In: Molecular Endocrinology (Baltimore, Md.) . 23, No. 7, July 2009, pp. 975-988. doi : 10.1210 / me.2008-0473 . PMID 19389808 .
- ↑ Chandalia A, Clarke HJ, Clemens LE et al. : MBX-102 / JNJ39659100, a Novel Non-TZD Selective Partial PPAR-gamma Agonist Lowers Triglyceride Independently of PPAR-alpha Activation . In: PPAR Research . 2009, 2009, p. 706852. doi : 10.1155 / 2009/706852 . PMID 19404482 . PMC 2673481 (free full text).
- ^ J. Xu: Metabolic Diseases Drug Discovery - Strategic Research Institute's Third International World Summit. PPAR and PTB1B modulators. In: IDrugs. 2004, 7, pp. 836-838.